Modern Chinese Medicine Group Reports Annual Loss of 13.557 Million Yuan

Stock News03-30

Modern Chinese Medicine Group (01643) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 145 million yuan, a decrease of 32.18% compared to the previous year. It reported an annual loss of 13.557 million yuan, contrasting with a profit of 9.67 million yuan in the same period last year. The basic loss per share was 2.05 cents. According to the announcement, the decline in revenue was primarily due to the loss of certain distributors. Among the factors, some of the group's best-selling products, such as Shan Mei Capsules, were not included in the national medical insurance list following healthcare reforms, leading to a drop in sales. Additionally, for other products that remained on the insurance list, reduced selling prices resulted in a decline in the overall gross profit margin.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment